Patents by Inventor Birong Zhang
Birong Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11976067Abstract: Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1-mediated disease, disorder, or condition in an individual.Type: GrantFiled: January 17, 2023Date of Patent: May 7, 2024Assignee: Maze Therapeutics, Inc.Inventors: Patrick Sang Tae Lee, Todd Jonathan August Ewing, Adam Neil Reid, Christopher Joseph Sinz, Birong Zhang, Sarah M. Bronner, David John Morgans, Jr., Maarten Hoek, Victoria Anne Assimon, Chris Ziebenhaus, Alexander Wayne Schammel
-
Publication number: 20230265096Abstract: Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1-mediated disease, disorder, or condition in an individual.Type: ApplicationFiled: January 17, 2023Publication date: August 24, 2023Inventors: Patrick Sang Tae LEE, Todd Jonathan August EWING, Adam Neil REID, Christopher Joseph SINZ, Birong ZHANG, Sarah M. BRONNER, David John MORGANS, Jr., Maarten HOEK, Victoria Anne ASSIMON, Chris ZIEBENHAUS, Alexander Wayne SCHAMMEL
-
Publication number: 20230045776Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: February 25, 2021Publication date: February 9, 2023Applicant: Genentech, Inc.Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
-
Publication number: 20220226326Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.Type: ApplicationFiled: August 23, 2021Publication date: July 21, 2022Applicants: Array BioPharma Inc., Genentech, Inc.Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do
-
Publication number: 20210253597Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: ApplicationFiled: January 20, 2021Publication date: August 19, 2021Applicant: GENENTECH, INC.Inventors: Steven MCKERRALL, Brian Salvatore SAFINA, Aleksandr KOLESNIKOV, Birong ZHANG, Wenfeng LIU, Kwong Wah LAI
-
Publication number: 20210236473Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: February 25, 2021Publication date: August 5, 2021Applicant: Genentech, Inc.Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
-
Patent number: 10966963Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: April 17, 2018Date of Patent: April 6, 2021Assignee: Genentech, Inc.Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
-
Patent number: 10947251Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: GrantFiled: March 29, 2019Date of Patent: March 16, 2021Assignee: GENENTECH, INC.Inventors: Steven McKerrall, Brian Salvatore Safina, Aleksandr Kolesnikov, Birong Zhang, Wenfeng Liu, Kwong Wah Lai
-
Publication number: 20200345735Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.Type: ApplicationFiled: January 7, 2020Publication date: November 5, 2020Applicants: Array BioPharma Inc., Genentech, Inc.Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do
-
Patent number: 10654867Abstract: Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: September 9, 2019Date of Patent: May 19, 2020Assignee: Genentech, Inc.Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Jiangpeng Liao
-
Publication number: 20200115354Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: ApplicationFiled: September 19, 2019Publication date: April 16, 2020Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.Inventors: Daniel SUTHERLIN, Steven MCKERRALL, Michael Scott WILSON, Kwong Wah LAI, Philippe BERGERON, Birong ZHANG, Ramsay BEVERIDGE, Jean-Philippe LECLERC, Alexandre LEMIRE, Liang ZHAO, Claudio STURINO
-
Publication number: 20200002353Abstract: Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: September 9, 2019Publication date: January 2, 2020Applicant: Genentech, Inc.Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Jiangpeng Liao
-
Patent number: 10457654Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: GrantFiled: October 31, 2017Date of Patent: October 29, 2019Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.Inventors: Daniel Sutherlin, Steven McKerrall, Michael Scott Wilson, Kwong Wah Lai, Philippe Bergeron, Birong Zhang, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Liang Zhao, Claudio Sturino
-
Publication number: 20190300544Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: ApplicationFiled: March 29, 2019Publication date: October 3, 2019Applicant: GENENTECH, INC.Inventors: Steven MCKERRALL, Brian Salvatore SAFINA, Aleksandr KOLESNIKOV, Birong ZHANG, Wenfeng LIU, Kwong Wah LAI
-
Publication number: 20190152970Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: January 17, 2019Publication date: May 23, 2019Applicant: Genentech, Inc.Inventors: Sharada LABADIE, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Zhiguo Liu, Tao Wang
-
Patent number: 10280149Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.Type: GrantFiled: July 7, 2017Date of Patent: May 7, 2019Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Brian K. Albrecht, Alexandre Cote, Victor Gehling, Vickie Hsiao-Wei Tsui, James Richard Jr. Kiefer, Jun Liang, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Birong Zhang
-
Publication number: 20180235945Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: April 17, 2018Publication date: August 23, 2018Applicant: Genentech, Inc.Inventors: SHARADA LABADIE, JUN LIANG, DANIEL FRED ORTWINE, XIAOJING WANG, JASON ZBIEG, BIRONG ZHANG, SIMON CHARLES GOODACRE, NICHOLAS CHARLES RAY, JUN LI, TOMMY LAI, JIANGPENG LIAO, ZHIGUO LIU, JOHN WAI, TAO WANG
-
Patent number: 10053451Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: May 25, 2016Date of Patent: August 21, 2018Assignee: Genentech, Inc.Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Birong Zhang, Nicholas D. Smith, Steven P. Govek, Mehmet Kahraman, Andiliy G. Lai, Johnny Y. Nagasawa, Simon Charles Goodacre, Nicholas Charles Ray
-
Patent number: 10035801Abstract: Provided are compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.Type: GrantFiled: March 13, 2014Date of Patent: July 31, 2018Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS INC.Inventors: Brian K. Albrecht, Steven F. Bellon, Victor S. Gehling, Jean-Christophe Harmange, Kwong Wah Lai, Jun Liang, Peter Dragovich, Daniel F. Ortwine, Sharada Labadie, Birong Zhang, James Richard Kiefer
-
Patent number: 10022354Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.Type: GrantFiled: April 7, 2017Date of Patent: July 17, 2018Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS INC.Inventors: Kwong Wah Lai, Jun Liang, Birong Zhang, Sharada Labadie, Daniel Ortwine, Peter Dragovich, James Kiefer, Victor S. Gehling, Jean-Christophe Harmange